29.07.2020

Class 3 Medicines Recall: Accord Healthcare Limited, Irinotecan Hydrochloride Concentrate for Solution for Infusion 20mg/ml (5ml vial), EL (20)A/33

Threat

Brief description of the problem: Accord Healthcare Limited is recalling the above batch as a precautionary measure, due to the observation of precipitation in the solution in the same batch marketed in another country (Malta). No complaints or adverse reaction reports have been received by the company to date for the UK product.

Find out more

Collapse the text

Source of the alert

MHRA

The risk concerns products

Product description

Irinotecan Hydrochloride Concentrate for Solution for Infusion 20mg/ml (5ml vial)

Active Pharmaceutical Ingredient: irinotecan hydrochloride

Recommendations for consumers
Advice for healthcare professionals

Stop supplying the above batch immediately. Quarantine all remaining stock and return these to your supplier using your supplier’s approved process.

Further Information

For more information or medical information queries, please contact:

Medinfo-BST

Tel: 01271 385257

E-mail: [email protected]

For stock control queries, please contact:

Accord-UK Ltd Customer Services Team

Tel: 0800 373573

E-mail: [email protected]

Fax: 01271 346106

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this notice.

NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Alert details

Country for notification

United Kingdom

Category

Pharmaceuticals

Country of origin

-

Source of the alert

MHRA - Medicines & Healthcare products Regulatory Agency, www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

Do you want to keep up with threats?

Download the application

Download our application and monitor threats! Scan products and feel safe every day. Check it out today!

Getwise Sp. z o.o.

Al. Ujazdowskie 22 lok 18
00-478 Warsaw, Poland

Copyright 2020 © Getwise Sp. z o.o. All rights reserved.